



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

9 April 2025
EMA/163919/2025
Veterinary Medicines Division

Committee for Veterinary Medicinal Products (CVMP)

CVMP assessment report for Nobilis Multiriva IBm+ND (EMA/V/C/006589/0000)

Vaccine common name: Avian infectious bronchitis virus and Newcastle disease virus vaccine (inactivated)

Assessment report as adopted by the CVMP with all information of a commercially confidential nature deleted.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Introduction	4
Vaccine Antigen Master file (VAMF) and vPTMF.....	4
Part 1 - Administrative particulars	5
Summary of the Pharmacovigilance System Master File.....	5
Manufacturing authorisations and inspection status	5
Overall conclusions on administrative particulars.....	5
Part 2 - Quality	6
Quality documentation (physico-chemical, biological, and microbiological information).....	6
Qualitative and quantitative composition	6
Container and closure system.....	6
Product development	6
Description of the manufacturing method	6
Production and control of starting materials.....	7
Starting materials listed in pharmacopoeias.....	7
Starting materials not listed in a pharmacopoeia	7
Control tests during the manufacturing process.....	8
Control tests on the finished product	8
Batch-to-batch consistency	8
Stability	9
Overall conclusions on quality.....	9
Part 3 – Safety documentation (safety and residues tests)	10
General requirements.....	10
Safety documentation	10
Pre-clinical studies	10
Safety of the administration of one dose	10
Safety of one administration of an overdose	10
Safety of the repeated administration of one dose	11
Examination of reproductive performance	11
Examination of immunological functions.....	11
User safety	11
Study of residues.....	11
MRLs	11
Withdrawal period.....	12
Interactions	12
Clinical studies	12
Environmental risk assessment.....	17
Overall conclusions on the safety documentation.....	17
Part 4 – Efficacy documentation (pre-clinical studies and clinical trials) ...	19
General requirements.....	19
Challenge model.....	19
Efficacy documentation.....	20
Pre-clinical studies	20
Clinical trials	25
Overall conclusion on efficacy	27

Part 5 – Benefit-risk assessment..... 29

Introduction..... 29

Benefit assessment..... 29

Risk assessment..... 30

Risk management or mitigation measures 31

Evaluation of the benefit-risk balance 31

Conclusion..... 32

Introduction

The applicant Intervet International B.V. submitted on 27 August 2024 an application for a marketing authorisation to the European Medicines Agency (The Agency) for Nobilis Multiriva IBm+ND, through the centralised procedure under Article 42(4) of Regulation (EU) 2019/6 (optional scope).

The eligibility to the centralised procedure was agreed upon by the CVMP on 22 May 2024 as no other marketing authorisation has been granted for the veterinary medicinal product within the Union.

At the time of submission, the applicant applied for the following indications:

For the active immunisation of chickens for:

- reduction of respiratory signs and egg drop caused by infectious bronchitis virus (IBV) strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype).
- reduction of mortality and clinical signs caused by Newcastle disease virus (NDV).

Onset of immunity:

IBV, NDV: 4 weeks post-vaccination.

Duration of immunity:

IBV, NDV: 80 weeks post-vaccination

Cross protection has been established for IBV strains QX-D388 (GI-19 genotype), Var2 (GI-23 genotype) and Q1 (GI-16 genotype).

Nobilis Multiriva IBm+ND is an emulsion for injection for chickens containing inactivated avian infectious bronchitis virus strain M41, inactivated avian infectious bronchitis virus strain 4/91, inactivated Newcastle disease virus strain Ulster and light liquid paraffin as adjuvant.

The vaccine is presented in packs containing 1 bottle of 300 ml (1000 doses) or 600 ml (2000 doses).

The vaccine is to be administered intramuscularly as a single dose of 0.3 ml in the breast or thigh region from 8 weeks of age onwards, but no later than 3 weeks before the onset of lay.

The rapporteur appointed is Jacqueline Poot and the co-rapporteur is Christine Miras.

The dossier has been submitted in line with the requirements for submissions under Article 8 of Regulation (EU) 2019/6 – full application.

On 9 April 2025, the CVMP adopted an opinion and CVMP assessment report.

On 2 June 2025, the European Commission adopted a Commission Decision granting the marketing authorisation for Nobilis Multiriva IBm+ND.

Vaccine Antigen Master file (VAMF) and vPTMF

VAMFs for Nobilis Multiriva IBm+ND (EMA/V/C/006589/0000) were assessed and approved in the context of the MAA for the parent product, Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS (EMA/V/C/005887/0000).

The following certificates were submitted with the application:

- IBV strain M41: EMA/V/VAMF/0002
- IBV strain 4/91: EMA/V/VAMF/0003
- NDV strain Ulster: EMA/V/VAMF/0004

Part 1 - Administrative particulars

Summary of the Pharmacovigilance System Master File

The applicant has provided a summary of the pharmacovigilance system master file which fulfils the requirements of Article 23 of Commission Implementing Regulation (EU) 2021/1281. Based on the information provided the applicant has in place a pharmacovigilance system master file (PSMF) has the services of a qualified person responsible for pharmacovigilance and has the necessary means to fulfil the tasks and responsibilities required by Regulation (EU) 2019/6.

Manufacturing authorisations and inspection status

Active substance

Three vaccine antigen master files certificates were submitted with this application; the GMP status for the manufacturers in these certificates is valid.

Finished product

Merck Sharp & Dohme Animal Health S.L., Salamanca, Spain, performs the manufacturing of the finished product.

A manufacturing authorisation was issued on 24 November 2020 by the competent authority of Spain (AEMPS). A GMP certificate confirming compliance with the principles of GMP is provided. The certificate was issued on 16 February 2022, referencing an inspection on 16 December 2021, by the competent authority of Spain (AEMPS).

Intervet International B.V., Wim de Körverstraat 35, 5831AN Boxmeer, the Netherlands, performs batch release. Proof of establishment in the EEA was provided.

A manufacturing authorisation was issued on 7 October 2022 by the Ministry of Agriculture, Nature and Food Quality of the Netherlands. A GMP certificate confirming compliance with the principles of GMP is provided. The certificate was issued on 22 January 2024, referencing an inspection on 28 – 31 August 2023, by the Ministry of Agriculture, Nature and Food Quality of the Netherlands.

Overall conclusions on administrative particulars

The summary of the pharmacovigilance system master file is considered to be in line with legal requirements. The GMP status of the active substances and of the finished product manufacturing sites has been satisfactorily established and is in line with legal requirements.

Part 2 - Quality

Quality documentation (physico-chemical, biological, and microbiological information)

Qualitative and quantitative composition

Nobilis Multiriva IBm+ND is an inactivated viral poultry vaccine presented in bottles containing 300 ml (1000 doses) and 600 ml (2000 doses).

The vaccine consists of the following antigens: inactivated avian infectious bronchitis virus (IBV) strain M41, inactivated avian infectious bronchitis virus (IBV) strain 4/91, and inactivated Newcastle disease virus (NDV) strain Ulster as active substances and light liquid paraffin as adjuvant.

Polysorbate 80, sorbitan oleate and PBS are included as excipients.

Container and closure system

The product is packed in a polyethylene terephthalate (PET) containers (compliant with Ph.Eur. 3.2.2, USP 661, USP 87 and USP 88), closed with halogenated butyl rubber stoppers (Ph.Eur. 3.2.9) and aluminium caps. Containers and stoppers are sterilised by ionising radiation at a minimum of 25 kGy. Example certificates of analysis for the packaging materials are provided in the dossier.

The container sizes are consistent with the vaccination schedule and intended use. The containers and closures are in compliance with the pharmacopoeial requirements, and their sterilisation is adequate.

Product development

The Nobilis Multiriva inactivated vaccine range can be regarded as the successor of the Nobilis inactivated vaccine range containing the inactivated avian metapneumovirus (AMPV), infectious bursal disease virus (IBDV), avian reovirus (ARV), egg drop syndrome virus (EDSV) (not present in this specific vaccine), infectious bronchitis virus (IBV) and Newcastle disease virus (NDV). The dose of Nobilis Multiriva vaccine range is 0.3 ml, compared to the dose of 0.5 ml of the Nobilis inactivated vaccine range manufactured by the applicant.

The IBV M41 antigen in Nobilis Multiriva IBm+ND vaccine is the same as in the Nobilis inactivated vaccine range. The IBV D274 strain was replaced by the IBV 4/91 strain, which is included to provide a broader protection and is globally more present. The NDV Clone 30 strain was replaced by the NDV Ulster strain, which is included to provide a broader protection in combination with live priming with NDV Clone 30. The adjuvant (oil phase of the emulsion) is the same as for the Nobilis inactivated vaccine range. The control tests were updated replacing animal testing where possible.

The antigens, adjuvant and excipients are qualitatively and quantitatively the same throughout the whole Nobilis Multiriva range.

Description of the manufacturing method

Active substances are manufactured as described in the respective vaccine antigen master files (VAMFs). For all antigens standard manufacturing methods are used. Virus strains are cultured mostly on primary chicken cells and are subsequently inactivated and concentrated where appropriate. The processes were appropriately validated, control tests are adequate to assure the quality and

consistency of the antigens.

The final product is manufactured by adding the inactivated antigen suspensions to PBS solution. Oil-soluble constituents (sorbitan oleate and polysorbate 80) are dissolved in liquid paraffin and the solution is sterilised. The oil solution and the aqueous suspension are subsequently mixed and emulsified. An example formulation calculation is provided.

Bottles are filled and closed with a stopper and secured with a cap. The final product is stored at 2-8°C.

The process is considered to be a standard manufacturing process for this type of vaccines. The major steps of the manufacturing process have been validated by three consecutive batches of the full-range finished product (Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS). It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible and consistent manner. The in-process controls are adequate for this type of manufacturing process.

Production and control of starting materials

Starting materials listed in pharmacopoeias

Starting materials listed in pharmacopoeias and used for manufacturing of antigens are listed in the respective VAMFs. Certificates of analysis have been provided, and all conform to the relevant specifications.

Starting materials listed in pharmacopoeias and used in the production of the finished product are:

Disodium phosphate dihydrate	Ph. Eur. Monograph 0602
Paraffin, light liquid	Ph. Eur. Monograph 0240
Polysorbate 80	Ph. Eur. Monograph 0428
Sodium chloride	Ph. Eur. Monograph 0193
Sodium dihydrogen phosphate dihydrate	Ph. Eur. Monograph 0194
Sorbitan oleate	Ph. Eur. Monograph 1041

Example certificates of analysis are provided for these starting materials, and all materials comply with Ph. Eur. requirements.

Starting materials not listed in a pharmacopoeia

Starting materials of biological origin

Starting materials of biological origin, not listed in pharmacopoeias and used for manufacturing of antigens are listed in the respective VAMFs. The seed materials are sufficiently characterised and appropriate tests have been performed to assure their quality. Other materials of biological origin conform to the in-house specifications as illustrated by certificates of analysis. The materials used conform to the requirements. No other starting materials of biological origin are used in the manufacturing of the finished product.

Starting materials of non-biological origin

Starting materials of non-biological origin, not listed in pharmacopoeias and used in the manufacturing of antigens are listed in the respective VAMFs. These materials are adequately described and of appropriate quality. No other starting materials of non-biological origin are used in the manufacturing of the finished product.

In-house preparation of media and solutions consisting of several components

Adequate information regarding the qualitative and quantitative composition of culture media used in the manufacturing of the antigens, their treatment processes and their storage conditions is provided in the respective VAMFs. The risk of contamination with extraneous agents was evaluated and considered negligible for each antigen.

Information regarding the qualitative and quantitative composition of solutions used in the manufacturing of the final product, their treatment processes and their storage conditions is provided in the dossier. All components are either tested for or treated to ensure that there are no contaminants.

An evaluation of the risk of presence of extraneous agents in the finished product is provided. The conclusion that the risk is practically zero is acceptable.

A TSE risk assessment on the finished product is provided in accordance with EMEA/410/01. The risk that the vaccine transmits TSE to chickens is estimated as practically zero.

Control tests during the manufacturing process

The control tests performed during the manufacture of the antigens are described in the respective VAMFs. These in-process control tests have been appropriately validated and are deemed to be sufficient to control all the critical steps in the manufacturing of the antigens.

The only control test performed during the manufacturing of the finished product is the filling volume. The relevant test method (weighing) is considered to fall under GMP. This in-process test is deemed to be sufficient to control the critical step in the manufacturing of the finished product.

Control tests on the finished product

A description of the methods used for the control of the finished product (appearance, viscosity, accelerated stability [stability of the emulsion], identity and potency, type of emulsion, free formaldehyde, sterility) and the respective specifications were provided.

The tests performed on the finished product were appropriately validated and appropriate limits have been set. The proposed tests are considered adequate to control the quality of the finished product.

Batch-to-batch consistency

The results of in-process and finished product testing on 3 consecutive batches of the full-range finished product (Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS) and one additional batch of Nobilis Multiriva RT+IBm+ND+Gm+REOm (no EDS antigen) are presented in tabular format. All batches conformed with all requirements; consistent results were obtained.

These batches are considered appropriate and the results representative also for this vaccine.

Stability

The stability of the bulk antigens is addressed in the respective VAMFs. From the data provided, the antigen's different storage periods have been adequately demonstrated.

The proposed shelf life of the product is 24 months at 2-8 °C. Long-term stability data are provided for a number of batches of the full-range product and fall-out products. Batches were tested for appearance, viscosity, sterility (at the end of the storage period, to confirm integrity of closure) and potency for each of the 3 antigens.

For all batches ($n=17$), appearance and viscosity conformed with the requirements throughout the 27-month storage period. Batches ($n=3$) remained sterile for up to 51 months. Potency for each of the antigens was tested at different times (in 5 to 26 batches) and was shown to remain stable and within specifications for at least 27 months of storage, thereby supporting the proposed 24-month shelf life.

Stability data were provided on vials from two batches stored for 3 days at 37 °C after broaching. Batches were fully tested and were shown to be stable. The data support the claimed 10-hour in-use stability at 20-25 °C.

Overall conclusions on quality

Nobilis Multiriva IBm+ND is an emulsion for injection for chickens containing inactivated avian infectious bronchitis strain M41, inactivated avian infectious bronchitis strain 4/91 and inactivated Newcastle disease virus strain Ulster as active substances, and light liquid paraffin as adjuvant. The vaccine is presented in packs containing 1 bottle of 300 ml (1000 doses) or 600 ml (2000 doses).

The manufacturing method consists of blending of the different components followed by emulsification and can be considered as standard for this type of vaccine. For each of the antigen components a Vaccine Antigen Master File is presented. For all antigens standard manufacturing methods are used. The processes were appropriately validated, and control tests are adequate to assure the quality and consistency of the antigens.

Procedures have been implemented to ensure the absence of extraneous agents in the starting materials of animal origin. A TSE risk assessment for the starting materials used is provided. The risk that the final product may transmit TSE to the target animal is considered to be practically zero.

The production method, including appropriate in-process controls and quality control on the finished product, together with control of the starting materials, generally ensure a consistent quality of batches of vaccine. The whole production process was evaluated at production scale and shown to be consistent.

The data provided support the proposed 24-month shelf life of the finished product. Stability data of broached product kept at elevated temperatures support the proposed 10-hour in-use shelf life at room temperature.

In conclusion, the production process is adequately described and controls in place are generally appropriate to ensure the quality of the product at release and throughout the shelf life.

Part 3 – Safety documentation (safety and residues tests)

General requirements

Nobilis Multiriva IBm+ND is presented as an emulsion for injection for chickens containing inactivated avian infectious bronchitis and inactivated Newcastle disease virus, as active substances; and liquid paraffin (mineral oil) as adjuvant. The vaccine is to be administered to chickens intramuscularly as a single dose of 0.3 ml in the breast or thigh region from 8 weeks of age onwards, but no later than 3 weeks before the onset of lay.

A full safety file in accordance with Article 8(1)(b) of Regulation (EU) 2019/6 has been provided.

Safety documentation

Five safety studies were conducted to investigate the safety of the product and included one pre-clinical study investigating the safety of the administration of one dose and four clinical trials. These studies were performed with the full-combination vaccine of the Nobilis Multiriva range (Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS). The use of the full-combination is considered as a worst-case scenario for safety and is as such acceptable.

Pre-clinical studies

Safety of the administration of one dose

One pivotal GLP safety study was provided. Safety of a single dose and of a double dose of the full-combination vaccine (Nobilis multiriva RT+IBm+ND+Gm+REOm+EDS) was studied in 7-week old SPF birds. In order to achieve the 200% antigen content multiple vaccine blends had to be used (not all components of the full combination can be blended at 200% in one preparation, due to space limitations). Groups of 11 birds received one of the following: a single dose of the complete full-combination vaccine (0.3 ml), a double dose of the complete vaccine (0.6 ml), a single dose of a vaccine containing AMPV and EDSV antigens blended at 200% (0.3 ml), a single dose of a vaccine containing IBV, NDV, IBDV and ARV antigens blended at 200% (0.3 ml) or a 1:1 mix of the two 200% antigen vaccines (0.6 ml).

During the 14-day observation period, birds were examined daily for clinical signs, intercurrent deaths and local reactions. None of the chickens showed abnormal signs of disease or died from causes attributable to vaccination during the observation period. No palpable local reactions were found in any of the birds. Post-mortem macroscopic and microscopic examinations were not performed.

On the basis of the results no safety concerns arose following the administration of the recommended dose or the double dose to chickens slightly below the minimum recommended age, providing therefore a valid demonstration of the safety of a single dose of the product. The absence of post-mortem data is considered justified, based on the high similarity of the composition of the product to the existing inactivated virus vaccines for poultry and the absence of palpable local reactions.

Safety of one administration of an overdose

No overdose studies are required for inactivated vaccines.

Safety of the repeated administration of one dose

The vaccine is to be given once during a lifetime. No repeated dose safety studies are therefore required.

Examination of reproductive performance

The vaccine is not intended for use during lay. Being an inactivated vaccine, the product is not considered a risk to the developing reproductive system. No specific studies were performed. In the field studies no differences were observed between vaccinated and control birds with respect to laying performance. A warning is included in the SPC not to use the product during lay or within 3 weeks before the onset of lay.

Examination of immunological functions

The product is an inactivated vaccine and none of the components are considered a risk for the immune system, therefore no studies were performed. This is acceptable.

User safety

The applicant has presented a user safety risk assessment which has been conducted in accordance with the CVMP 'Guideline on user safety for immunological veterinary medicinal products' (EMA/CVMP/IWP/54533/2006) as well as the CVMP 'Guideline on user safety for pharmaceutical veterinary medicinal products' (EMA/CVMP/543/03-Rev.01).

The main potential routes of accidental contact with the product have been considered, and it was concluded that the most likely are those of accidental self-injection and dermal and/or oral exposure.

The active substances are inactivated viruses which are not infectious to humans. The excipients are commonly used in other vaccines and do not present a safety concern. However, the light mineral oil included in the formulation is of concern for the user since an accidental self-injection may have consequences that could, in the worst-case, lead to loss of a digit due to blockage of blood vessels as a result of the pressure caused by inflammatory reactions.

As a result of the user safety assessment, adequate information is included in section 3.5 of the SPC and, since the product contains mineral oil, the standard warning for mineral oil-containing vaccines is appropriately included in the product literature.

Based on the above user risk assessment, the CVMP concluded that the product does not pose an unacceptable risk to the user when used in accordance with the SPC.

Study of residues

No studies of residues were performed. This is considered acceptable.

MRLs

The active substances, being a principle of biological origin intended to produce active immunity, are not within the scope of Regulation (EC) No 470/2009.

The excipients, including adjuvants, listed in section 2 of the SPC are either allowed substances for which Table 1 of the Annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are

required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.

The antimicrobial substances used in the manufacturing of the antigens are present at low residual levels in the finished product. At these levels, they are devoid of pharmacological activity and are not considered to constitute a risk for the consumer.

Withdrawal period

The withdrawal period is set at zero days.

Interactions

The applicant has not provided data investigating interactions of the vaccine with any other veterinary medicinal product and therefore proposes to include a statement in Section 3.8 of the SPC that 'No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.' This is considered acceptable.

Clinical studies

Four single-centre, non-randomised, open, positive-controlled, two-armed GCP-compliant clinical studies with matched flocks were conducted to evaluate safety and efficacy in layer and broiler breeders. The studies were conducted in the Netherlands in well-managed farms.

All four studies were well designed and conducted and confirmed that the product is safe in both layer and broiler breeders when applied as part of the standard vaccination program.

Study 1: A field trial in the Netherlands to assess the safety and efficacy of a RT+IBm+ND+Gm+REOm+EDS vaccine in breeders	
Study sites	Broiler breeder farm in the Netherlands, matched houses.
Study design	Open, positive controlled, two-armed (matched flocks).
Compliance with regulatory guidelines	GCP compliant
Animals	Conventional broiler breeders, originating from the same parent flocks and of the same age, were evenly distributed over the houses to obtain identical flocks of approximately 18,000 birds.
Test product	Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, 0.3 ml, i.m.
Control product	Nobilis RT+IBmulti+G+ND 0.5 ml, i.m. plus Nobilis Reo inac. 0.5 ml i.m.
Vaccination scheme	Birds in the test group were vaccinated with the test product in the 14 th week of life (right side breast muscle) while birds in the control group were vaccinated with the two control vaccines (in right and left side breast muscle). Prior to and after the 14 th week, both flocks received all standard vaccinations for the farm.

Safety end points	Daily general health and feed intake for 2 weeks post vaccination (p.v.). Local reactions scored on 15 randomly selected birds in each group on days 1, 4, 7 and 14 p.v. and weekly thereafter until resolved. Egg production and hatchability was monitored for each group throughout the period of lay. Throughout the study, daily mortality, vaccinations and the use of medication were recorded.
Statistical method	Descriptive statistics (two groups)
Results	
Outcomes-Safety observations	General health and feed intake were scored as normal on all observation days. A local reaction was observed in one bird (out of 15 tested) of the control group on day 7. In the test group on day 4, one bird showed a 2 cm long subcutaneous haemorrhage in the right breast, likely a result of mechanical trauma. On day 14 one bird had a large (10 x 3.5) subcutaneous reaction in the right breast. This concerned a hard swelling showing signs of inflammation (swollen and red). The bird was in good general condition. An additional scoring on day 20 revealed no further local reactions. The mortality numbers were similar in both groups and comparable to normal mortality figures for this type of bird. Egg production was good and highly comparable between groups. Fluctuations were due to general causes and detectable in both groups. Hatchability was highly similar.
Adverse events	Local reactions were observed both in the test and control groups.
Discussion	
Discussion/conclusions further to assessment	<i>The study was appropriately designed and conducted to an acceptable standard (GCP). While some local reactions were observed in the test group (but also in the control group), this did not lead to any changes in the performance of the flock when compared to the positive control group.</i> <i>The study is considered to support the safety of the vaccine when applied under field conditions.</i>

Study 2, A field trial in the Netherlands to assess the safety and efficacy of the RT+IBm+ND+Gm+REOm+EDS vaccine in layers	
Study sites	Layer farm in the Netherlands, matched houses.
Study design	Open, positive controlled, two-armed (matched flocks).
Compliance with regulatory guidelines	GCP compliant
Animals	Conventional layers, originating from the same parent flocks and of the same age, were evenly distributed to obtain identical groups.

	Groups were housed in different rows of the rearing house and later placed in two houses to obtain identical flocks of approximately 10,000 birds.
Test product	Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, 0.3 ml, i.m.
Control product	Nobilis RT+IBmulti+G+ND 0.5 ml, i.m.
Vaccination scheme	Birds in the test group were vaccinated with the test product in the 12 th week of life (right side breast muscle) while birds in the control group were vaccinated with the control vaccine (right side breast muscle). Nobilis Salenvac T was applied at the same time as the study products, in the left breast muscle. Prior to and after the 12 th week, both flocks received all standard vaccinations for the farm.
Safety end points	Daily general health and feed intake for 2 weeks post vaccination (p.v.). Local reactions scored on 15 randomly selected birds in each group on days 1, 4, 7 and 14 p.v. and weekly thereafter until resolved. Egg production was monitored for each group throughout the period of lay. Throughout the study, daily mortality, vaccinations and the use of medication were recorded.
Statistical method	Descriptive statistics (two groups)
Results	
Outcomes-Safety observations	General health and feed intake were scored as normal on all observation days. Local reactions were not observed in control or test group. The mortality numbers were similar in both groups and comparable to normal mortality figures for this type of bird. Egg production was not correctly registered in the first weeks of the study. After the correction of the egg counter malfunction from week 27 egg production was comparable between groups.
Adverse events	No immediate or local reactions observed.
Discussion	
Discussion/conclusions further to assessment	<i>The study was appropriately designed and conducted to an acceptable standard (GCP). No general or local reactions were observed, and performance of the test and control groups was highly similar and within normal ranges. The study is considered to support the safety of the vaccine when applied in layers under field conditions.</i>

Study 3, A field trial in the Netherlands to assess the safety and efficacy of the RT+IBm+ND+Gm+REOm+EDS vaccine in layers

Study sites	Layer farm in the Netherlands, matched houses.
-------------	--

Study design	Open, positive controlled, two-armed (matched flocks).
Compliance with regulatory guidelines	GCP compliant
Animals	Conventional layers, originating from the same parent flocks and of the same age, were evenly distributed to obtain identical groups. Groups were housed in different rows of the rearing house and later placed in two houses to obtain identical flocks of approximately 12,500 birds.
Test product	Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, 0.3 ml, i.m.
Control product	Nobilis RT+IBmulti+G+ND 0.5 ml, i.m.
Vaccination scheme	Birds in the test group were vaccinated with the test product in the 12th week of life (right side breast muscle) while birds in the control group were vaccinated with the two control vaccines (in right and left side breast muscle). Avian encephalomyelitis/fowl pox vaccine was applied via wing web and Nobilis ILT via ocular route at the same time as the test and control vaccines. Prior to and after the 12th week, both flocks received all standard vaccinations for the farm.
Safety end-points	Daily general health and feed intake for 2 weeks post vaccination (p.v.). Local reactions scored on 15 randomly selected birds in each group on days 1, 4, 7 and 14 p.v. and weekly thereafter until resolved. Egg production was monitored for each group throughout the period of lay. Throughout the study, daily mortality, vaccinations and the use of medication was recorded.
Statistical method	Descriptive statistics (two groups)
Results	
Outcomes-Safety observations	General health and feed intake were scored as normal on all observation days. Local reactions were not observed in the test or control groups. Mortality was similar in both groups and somewhat higher than normal, which was attributed to feather pecking. Egg production was within normal ranges and comparable between groups.
Adverse events	Immediate or local reactions were not observed.
Discussion	
Discussion/conclusions further to assessment	<i>The study was appropriately designed and conducted to an acceptable standard (GCP). No general or local reactions were observed, and performance of the test and control groups was highly similar and within normal ranges. The study is considered to support the safety of the vaccine when applied in layers under field conditions.</i>

Study 4, A field trial in the Netherlands to assess the safety and efficacy of the RT+IBm+ND+Gm+REOm+EDS vaccine in broiler breeders primed with REOm	
Study sites	Broiler breeder farm in the Netherlands, matched houses.
Study design	Open, positive controlled, two armed (matched flocks).
Compliance with regulatory guidelines	GCP compliant
Animals	Conventional broiler breeders, originating from the same parent flocks and of the same age, were evenly distributed over the houses to obtain identical flocks of approximately 12,000 birds.
Test product	Nobilis Multiriva REOm 0.3 ml, i.m. Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, 0.3 ml, i.m.
Control product/ Placebo	Nobilis Reo 1133 (0.2 ml) plus Nobilis RT+IBmulti+G+ND 0.5 ml, i.m. plus Nobilis Reo inac. 0.5 ml i.m.
Vaccination scheme	Birds in the test group were vaccinated with the test product in the 8 th week of life (Nobilis Multiriva REOm) and 12 th week of life (Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS). Birds in the control group were vaccinated in the 8 th week of life with Nobilis Reo 1133 and in the 12 th week with Nobilis RT+IBmulti+G+ND 0.5 ml, i.m. plus Nobilis Reo inac. Concurrent with the vaccination at 8 weeks of age, birds were vaccinated via wingweb with Tremvac. Prior to and after these vaccinations, both flocks received all standard vaccinations for the farm.
Safety end points	Daily general health and feed intake for 2 weeks post vaccination (p.v.). Local reactions scored on 15 randomly selected birds in each group on days 1, 4, 7 and 14 p.v. and weekly thereafter until resolved. Egg production and hatchability was monitored for each group throughout the period of lay. Throughout the study, daily mortality, vaccinations and the use of medication was recorded.
Statistical method	Descriptive statistics (two groups)
Results	
Outcomes-Safety observations	Some data could not be collected as planned due to COVID-19 restrictions (hatchability data). General health and feed intake was scored as normal on all observation days. A local reaction was observed in one bird (out of 15 tested) in the test group on day 7 (subcutaneous haemorrhage, Nobilis Multiriva REOm) and in one bird on Day 15 (hard nodule in right breast 3x1

	cm, Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS vaccination), the birds looked otherwise healthy. No local reactions were found one week later. Local reactions were found in one bird of the control group on Day 15 (mild subcutaneous inflammation in the right breast: Nobilis RT+IB multi+G+ND vaccination). The mortality numbers were similar in both groups and comparable to normal mortality figures for this type of bird. Egg production was good and highly comparable between groups. Hatchability was tested once and was similar.
Adverse events	Local reactions were observed both in the test and control groups.
Discussion	
Discussion/conclusions further to assessment	<i>The study was appropriately designed and conducted to an acceptable standard (GCP). While some local reactions were observed in the test group (but also in the control group), this did not lead to any changes in the performance of the flock when compared to the positive control group.</i> <i>The study is considered to support the safety of the vaccine when applied to broiler breeders under field conditions.</i>

Environmental risk assessment

An environmental risk assessment (ERA) has been performed in accordance with the 'Note for guidance on environmental risk assessment for immunological veterinary medicinal products' (EMA/CVMP/074/95-Final). It is concluded that the ERA can stop in Phase I.

The product is a vaccine containing inactivated viral poultry antigens and is adjuvanted with light liquid paraffin. Polysorbate 80, sorbitan oleate and PBS are included as excipients. The product is used in chickens and is administered intramuscularly. Therefore, direct exposure of the environment to the product does not take place. Any unused product or waste material does not pose an environmental risk. The product and waste should nevertheless be disposed by the appropriate channels, and adequate advice is given in the product literature. As no live microorganisms are present in the product, hazards and risks from the active ingredients are considered negligible. Excretion of any of the active compounds of the product or their metabolites by vaccinated animals, if occurring at all, will only be in minimum amounts and does not pose a risk to the environment. In conclusion, this veterinary medicinal product is not expected to pose a risk for the environment when used according to the SPC.

Overall conclusions on the safety documentation

The safety of a standard dose and a double dose of the full range vaccine was tested in a GLP study. These data are acceptable for all fall-out vaccines as well. The vaccine is blended to contain a standard dose of each antigen and thus there are no minimum or maximum potency vaccine batches. From the results it can be concluded that the vaccine is safe in birds from 7 weeks of age, when applied in accordance with the SPC.

The vaccine is to be applied once during the production lifetime of the birds. No repeated dose safety

studies are therefore required.

The vaccine is not intended for use during lay. Being an inactivated vaccine, the product is not considered a risk to the developing reproductive system. No specific studies were performed, and this is acceptable. A warning is included in the SPC to not use the product during lay or within 3 weeks before the onset of lay.

The product is an inactivated vaccine and none of the components are considered a risk for the immune system, therefore no studies were performed. The absence of specific studies or data on immunological functions is adequately justified.

The results of four field safety and efficacy field trials performed with the full range vaccine indicated no safety issues. The data are considered to support the safety of the vaccine when used in field conditions. In the field trials, no differences were observed between vaccinated and control birds with respect to laying performance, supporting the notion that the product does not pose a risk to the developing reproductive system when used as recommended.

A comprehensive user safety assessment has been provided by the applicant. Mineral oil was identified as the major ingredient of concern for the user. Therefore, the standard warning for mineral-oil-containing vaccines is included in the product information, which is considered appropriate. The user safety has been adequately addressed and appropriate warnings are included in the SPC.

Based on the data provided, the ERA can stop at Phase I. The product is not expected to pose a risk for the environment when used according to the SPC.

The applicant has provided a comprehensive risk assessment on residual antibiotics in the finished product. Residue studies are not required. The withdrawal period is set at zero days.

In conclusion, when used as recommended, the vaccine is considered to be safe for the target animal, the environment, the user and the consumer.

Part 4 – Efficacy documentation (pre-clinical studies and clinical trials)

General requirements

The applicant applied for the following claims:

- Target species: Chickens
- Method of administration: Intramuscular injection
- Dose: 0.3 ml

Indication for use:

For the active immunisation of chickens for:

- reduction of respiratory signs and egg drop caused by infectious bronchitis virus strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype).
- reduction of mortality and clinical signs caused by Newcastle disease virus.

Onset of immunity:

- 4 weeks post-vaccination

Duration of immunity:

- 80 weeks post-vaccination

Cross-protection has been established for IBV strains QX-D388 (GI-19 genotype), Var2 (GI-23 genotype) and Q1 (GI-16 genotype).

The vaccine is intended for use in chickens that have received primary vaccinations with live or inactivated vaccines against infectious bronchitis virus (e.g. Nobilis IB 4-91, Nobilis IB Ma5). This requirement is included in the SPC section 3.9. Therefore, data derived from studies in chickens that had received such prime-boost vaccinations were used for IBV to support onset and duration of efficacy. For NDV, the efficacy was determined in studies in non-primed birds, receiving only vaccination with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS. The use of the full-combination product for efficacy studies is considered a worst-case scenario and as such is acceptable.

Efficacy studies were conducted in accordance with:

EMA/CVMP/IWP/206555/2010: Guideline on requirements for the production and control of immunological veterinary products

Ph. Eur. 0062: Vaccines for veterinary use, Ph. Eur. 5.2.7: Evaluation of efficacy of veterinary vaccines and immunosera, Ph. Eur. 0959: Avian infectious bronchitis vaccine (inactivated), Ph. Eur. 0870: Newcastle disease vaccine (inactivated).

Challenge model

In order to demonstrate a broad protection against all genotype-I IBV strains, the following challenge strains were used: M41 (GI-1), 4/91 (GI-13), QX (GI-19), Var2 (GI-23) and Q1 (GI-16). These challenge strains cover the different viral lineages within the genotype I cluster. The vaccination challenge studies were set up in accordance with the Ph. Eur. monographs 0959 and 5.2.7 and as such

are considered acceptable. Both the ocular and intratracheal routes of challenge were used to induce a drop in egg production and eggshell defects. As IBV-specific antibodies are related to protection, serological analysis (HI assay) was performed in pre-clinical and clinical studies, and this is considered a relevant indicator of the developing/ongoing immune response.

Efficacy studies for NDV were set up following the Ph. Eur. monographs 0870 and 5.2.7, using the Herts 33/56 challenge strain. Since the ND virus has only one serotype, no other challenge strains are needed to demonstrate protection. The main clinical parameters to assess the efficacy of the vaccine after an experimental challenge are clinical signs and mortality. Since NDV-specific antibodies are related to protection, serological analysis was performed in pre-clinical and clinical studies, and this is considered a relevant indicator of the developing/ongoing immune response.

Efficacy documentation

Laboratory studies were well documented and carried out in chickens of the minimum age for vaccination, using pilot batches. Pilot batches were also used in the clinical trials. In all of these studies, the full-combination vaccine was used. These data are considered appropriate to support the efficacy of fall-out vaccines like Nobilis Multiriva IBm+ND.

Studies include the onset of immunity (OOI) studies, duration of immunity (DOI) studies and studies to demonstrate protection at peak of lay and cross-protection against other strains.

Pre-clinical studies

Dose determination

Since the vaccine range Nobilis Multiriva can be considered as an update and extension of the existing range of Nobilis inactivated vaccines, it is accepted that the vaccine (antigen) doses have been established based on prior experience.

Onset of immunity

IBV

In one pre-clinical study, serological responses to IBV and AMPV after vaccination were analysed. Day-old SPF hens were divided into 4 groups of 20 birds. One group was left untreated (control), one group was vaccinated at Day 0 with live AMPV vaccine (Nobilis Rhino CV) and at 15 weeks with the test vaccine (Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS), one group was vaccinated at Day 0 with live IB vaccines (Nobilis IB Ma5 and Nobilis IB 4-91) and at 15 weeks with the test vaccine (Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS), and one group was vaccinated with the test vaccine at 15 weeks (Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS).

Blood samples were taken regularly from all treatment groups up to 99 weeks of age. Antibodies against IBV M41 and IBV 4/91 were determined by HI test. Overall, similar serological profiles for both anti-IBV M41 and anti-IBV 4/91 antibodies were observed for each individual treatment group, albeit the average titres were higher for anti-IBV 4-91 antibodies. From 20 weeks of age, birds in the non-vaccinated treatment group showed levels of non-specific reactivity for both anti-IBV M41 antibodies and anti-IBV 4/91 antibodies, typical of the age of the birds ($\leq 5 \log_2$). Priming with live Nobilis IB vaccines induced an initial IBV antibody response peaking at around 8 to 12 weeks of age, at around $7-8 \log_2$. Following boosting with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS the antibody levels increased to around $11 \log_2$ and these levels persisted with a slight decline until at

least 90 weeks of age. Non-IBV primed birds showed a clear response following administration of the inactivated vaccine, but the titres achieved were lower than in the IBV-primed birds (8-9 log₂). At the 99-week timepoint, titres had increased in all groups except the IBV live group. This was likely an effect of IBV exposure, so no conclusions can be drawn after week 90. It can be concluded that an antibody response was detectable from 5 weeks until 75 weeks post vaccination. The serological data from this study were compared with the IBV serology in another study. Birds were vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS at 16 weeks of age and blood samples were collected at 20 weeks of age (4 weeks p.v.).

The titres obtained at 5 weeks p.v. and at 4 weeks p.v. are highly similar, supportive of an onset of immunity of 4 weeks p.v.

Several studies were performed to assess the protection of Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS against IBV challenge.

In the first study, four groups of 40 day-old SPF birds were included. One group was left untreated (control), one group was vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS at 15 weeks of age, one group was vaccinated at day of age with live Nobilis IB Ma5 vaccine and at 15 weeks with the Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS (prime-boost) and one group was vaccinated with live Nobilis IB Ma5 vaccine at day of age (live IBV). At 15 weeks of age each group was divided into 4 pens; egg production and quality were recorded per pen. At 26 weeks of age, the birds were challenged with IBV M41 via ocular route and monitored for 4 weeks. In the controls, the maximum egg drop was 18.6%, which is below the requirements for a valid test according to Ph. Eur. 0959 (35%). The average post-challenge egg production in the vaccinated groups was higher by 10% (test vaccine), 12% (live IBV) or 13% (prime-boost) compared to the controls. The study met the requirements of the WOAHS terrestrial manual for egg drop in the controls (>15%) and the vaccinated (prime-boost) group experienced no drop in egg production, indicating complete protection. In other studies, with challenges at later stages after vaccination, a more pronounced drop in egg production was achieved in controls, while again the vaccinates were protected. It is agreed that following the 3Rs principle, it is not desirable to repeat the study for protection at peak of lay.

The set-up of the second study was similar to the previous one, but birds were challenged with the IBV 4/91 strain. Egg drop in the controls was 5% at 2 weeks post challenge, so the study was considered invalid.

The third study included 4 groups of 55 day-old SPF birds. One group was left untreated (control), one group was vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS at 16 weeks of age, one group was vaccinated at day of age with live IBV 4/91 vaccine and at 16 weeks with the test vaccine (prime-boost), and one group was vaccinated with live IBV 4/91 vaccine at day of age (live IBV). At 18 weeks of age, 48 animals in each group were divided into 4 pens per group; egg production and quality were recorded per pen. At 27 weeks of age, the birds were challenged with IBV 4/91 via intratracheal route and monitored for 4 weeks. The challenge did not result in a strong effect on average egg production (-13.8% in controls) and is not valid in accordance with Ph. Eur. 0959 requirements (at least 15% reduction). Moreover, it is noted that the vaccinated group with the lowest antibody response (live IBV) had no drop in egg production, whereas the test vaccine and prime-boost groups did show a reduction in egg production that was small (5%) but statistically significant. It can be agreed that the reductions in egg production in the vaccinated groups after challenge are small and may not be biologically significant. Taken together, these data give only very limited support for the test vaccine efficacy against IBV 4/91 challenge at peak of lay (11 weeks post vaccination). However, at 45 and 81 weeks post vaccination, full protection against drop in egg production due to IBV 4/91 challenge was found in birds that were primed with live IBV vaccines and

boosted with Multiriva RT+IBm+ND+Gm+REOm+EDS. This is considered adequate to support efficacy against IBV 4/91.

A different study was performed where birds were primed with live IBV vaccines (Nobilis IB Ma5 and Nobilis IB 4-91) at day of age, and boosted with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS at 15 weeks. At 25 weeks post vaccination, the birds were challenged with IB-QX virus. Controls exhibited a clear drop in egg production, which was prevented in the vaccinates. Another study had the same design but the challenge was performed with IBV variant 2. Again, controls exhibited a clear drop in egg production, which was prevented in the vaccinates. Finally, the applicant provided a new study, in which birds that had received a priming and booster vaccination were challenged at 11 w.p.v. with IBV Q1. Full protection against egg drop was observed in the vaccinates.

From the totality of data derived from the IB vaccination-challenge studies, it can be concluded that vaccination with a prime-boost schedule resulted in a reduction of coughing after challenge with IBV strains. Thus, protection against respiratory signs caused by IBV M41, IBV 4/91, IBV QX and IBV Var2 can be considered adequately supported by data.

In conclusion, the claimed onset of immunity against IBV of 4 weeks is sufficiently supported by data. Taking into account the indication of the vaccine as a booster after live or inactivated IBV priming, adequate data supporting protection from egg drop at peak of lay are available for IBV M41, QX, Q1 and Var2 types.

NDV

In the first study, serological responses to NDV were evaluated. Seven groups of 34 to 38 day-old SPF chicks were included in the study: one group remained unvaccinated, two groups were vaccinated at day of age with Nobilis ND C2, another two groups were vaccinated at day of age with Nobilis ND Clone 30 and the last two groups were not vaccinated at Day 0. At 12 weeks of age, all vaccinated groups received Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS. Blood samples from 15 birds per group were collected at regular intervals. Antibody responses were evaluated by HI test using NDV La Sota and NDV Ulster antigens. Titres in the non-vaccinated controls remained at baseline levels throughout the study. No titres were observed in the non-primed birds prior to vaccination. Priming with live Nobilis ND vaccines induced an initial low anti-NDV antibody response. Following boosting with the inactivated vaccine, the antibody levels strongly increased, and then slowly declined by 30 weeks of age and remained stable up to 100 weeks of age. Titres after single vaccination were lower but clearly detectable from 4 weeks post-vaccination (p.v.) and decreased somewhat by 30 weeks of age to remain stable until 100 weeks of age. The study was appropriately designed and executed, and the results support an onset of immunity of 4 weeks post vaccination and a duration of immunity of 100 weeks of age (88 weeks post vaccination).

The second study was designed fully in accordance with the Ph. Eur. 0870 test for immunogenicity. Three batches of Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS were included in the test: blended at 100%, 75% and 50% of the target NDV antigen quantity. For all three vaccine batches, three dilutions (1/30th, 1/50th and 1/120th dose) were tested for protection against NDV Herts 33/56 challenge. The test can be considered valid, since all control birds died within 6 days of challenge. The vaccine complied with the test, since the smallest dose (minimum antigen content = 100% batch) corresponded to no less than 50 protective dose 50% (PD₅₀) and the lower confidence limit is no less than 35 PD₅₀. The batches blended at 75% and 50% NDV antigen also complied with the test requirement.

In the third study, a total of 105 day-old SPF birds were included, divided into 7 groups. The groups were either not vaccinated (control), vaccinated at 12 weeks of age with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, primed with Nobilis ND C2 and boosted with the test vaccine or primed with Nobilis ND Clone 30 and boosted with the test vaccine. All groups were challenged at 16 weeks of

age with NDV Herts 33/56 and the birds were monitored for 21 days for clinical signs. All control birds were euthanised within 4 days after the challenge due to signs of NDV. The results support an onset of immunity of 4 weeks, with 93.3% - 100% protection against clinical signs and mortality after vaccination with Nobilis Multiriva RT+IBm+ND+EDS+Gm+REOm with or without priming with Nobilis ND C2 or Nobilis ND Clone 30.

In conclusion, taking together the results from serological and challenge studies, the claimed onset of immunity (reduction of mortality and clinical signs) against NDV of 4 weeks is considered sufficiently supported by the data provided.

Duration of immunity

IBV

Serological responses to IBV after vaccination were analysed (see OOI above). It can be concluded that an antibody response against IBV M41 and IBV 4/91 was detectable at least until 75 weeks after vaccination (last reliable sample).

Eight studies were performed in which birds were vaccinated against IB using a priming vaccination with IBV live vaccine(s) and a booster vaccination with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, and subsequently challenged with IBV.

In the first study, two groups of 20 day-old SPF hens were included. One group remained unvaccinated (control), the other was vaccinated at day of age with live Nobilis IB Ma5 and Nobilis IB 4-91 vaccines and at 15 weeks of age with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS. At 57 weeks of age each group was divided over three pens, and egg production and quality were monitored. Challenge with IBV M41 was performed at 60 weeks of age and birds were monitored for 4 weeks. In the control group, reductions in egg production up to 60.5% were observed. In the vaccinated group there was minimal effect of challenge (6.6% reduction). The study provides support for a duration of immunity of 45 weeks post vaccination in birds primed with live Nobilis IB Ma5 and Nobilis IB 4-91 vaccine and vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS against virulent challenge with IBV Massachusetts M41 strain.

Study 2 was set up identically to the study described above, but with challenge at 96 weeks of age. A significant reduction in egg production was observed in the control group (up to 50%), while in the vaccinated group a smaller effect (13%) was observed at 2 weeks post challenge. The study provides support for a duration of immunity of 81 weeks post vaccination in birds primed with live IBV Ma5 and IBV 4/91 vaccine and vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS against virulent challenge with IBV Massachusetts M41 strain.

Study 3 was set up identically to study 1, with the exception of the challenge that was performed (at 60 weeks of age) with IBV 4-91 strain. In the control group, egg production decreased (up to 24% decrease) in the first two weeks after challenge. In the vaccinated group, egg production remained at pre-challenge level. The study provides support for a duration of immunity of 45 weeks post vaccination in birds primed with live IBV Ma5 and IBV 4/91 vaccine and vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS against challenge with variant IBV 4/91 strain.

Study 4 was set up identically to the study 3 described above, but with challenge at 96 weeks of age. A significant reduction in egg production was observed in the control group (up to 42%), while in the vaccinated group egg production remained at pre-challenge level. The study provides support for a duration of immunity of 81 weeks post vaccination in birds primed with live IBV Ma5 and IBV 4/91 vaccine and vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS against challenge with variant IBV 4/91 strain.

In study 5 two groups of 30 day-old SPF hens were included. One group remained unvaccinated (control), the other was vaccinated at day of age with Nobilis IB Ma5 and Nobilis IB 4-91 vaccines and at 15 weeks of age with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS. At 33 weeks of age each group was divided over three pens, and the egg production and quality were monitored. Challenge with IBV QX strain was performed at 40 weeks of age and the birds were monitored for 4 weeks. In the control group, reductions in egg production up to 50.6% were observed. In the vaccinated group there was some effect of challenge (9.3% reduction). The study provides support for protection against egg drop caused by IBV QX strain at 25 weeks post vaccination in birds vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, when primed with live IBV vaccines at one day of age.

Study 6 was designed identically to study 5 described above, but for the challenge performed with Q1 strain of IBV. No effect of challenge was observed in either of the two groups and the study was considered invalid.

Study 7 was designed identically to the study 5 (described above), except for the challenge strain used: IBV variant 2. Control birds exhibited significant reductions in egg production following challenge (max. 36.1%). In the vaccinated birds, mean weekly egg production was slightly reduced (< 10% of baseline). After challenge, the level of abnormal eggs was higher in the vaccinated group (8.5%) than in the control group (3.9%). The effect on the egg production was re-evaluated by subtracting the abnormal eggs. The evaluation showed that the overall egg production using only well-formed eggs in the four-week period after challenge was significantly higher in the vaccinated birds compared to the non-vaccinated birds. The results are considered to support protection against egg drop caused by IBV Variant 2 strain at 25 weeks post vaccination in birds vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, when primed with live IBV vaccines at one day of age.

In the last study, birds that received a priming and booster vaccination were challenged at 11 w.p.v. with IBV Q1. Full protection against egg-drop was observed in the vaccinates.

In conclusion, the serological response to IBV M41 and IBV 4/91 antigens could be reliably detected until 75 weeks post vaccination (non-primed). Challenge data have been provided that support protection after a prime-boost schedule (live IBV vaccines followed by Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS). These data support efficacy against IBV M41 and 4/91 challenge at up to 81 weeks post vaccination. Together, the data are considered to support the claimed DOI for IBV of 80 weeks post vaccination.

In addition, efficacy of the prime-boost regimen against IBV QX and IBV Var2 challenge at 25 weeks, or against IBV Q1 challenge at 11 weeks post vaccination was shown. Since it is accepted that antibodies are a correlate of protection for IBV, the serological OOI and DOI as determined for IBV M41 and IBV 4/91 strains is also valid for the variant strains that depend on cross-reactivity of the antibodies generated against IBV M41 and IBV 4/91 antigens in the vaccine. A claim for cross-protection against IBV QX, IBV Var2 and IBV Q1, separately included in the SPC, is therefore accepted.

NDV

The serological study (described above for OOI) provides support for an immune response that is maintained at a stable level until 88 weeks post vaccination.

Study 1 included a total of 126 day-old SPF chicks divided into 7 groups. Groups were either not vaccinated (control), vaccinated at 12 weeks of age with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, primed with Nobilis ND C2 and boosted with the test vaccine or primed with Nobilis ND Clone 30 and boosted with the test vaccine. All groups were challenged at 60 weeks of age with NDV Herts 33/56, and birds were monitored for 21 days for clinical signs. Twelve out of thirteen control birds died of NDV. The vaccinated groups were significantly protected (80-100%). The results support a duration of immunity of 48 weeks, with protection against clinical signs and mortality

after vaccination with Nobilis Multiriva RT+IBm+ND +Gm+REOm+EDS with or without priming with Nobilis ND C2 or Nobilis ND Clone 30.

In studies 2 and 3, the efficacy of the NDV component at 100 weeks of age was tested. A total of 126 day-old SPF chicks were divided into 6 groups. Groups were either not vaccinated (control), vaccinated at 12 weeks of age with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, primed with Nobilis ND C2 and boosted with the test vaccine or primed with Nobilis ND Clone 30 and boosted with the test vaccine. All groups were challenged at 100 weeks of age with NDV Herts 33/56, and the birds were monitored for 21 days for clinical signs. All controls died or were euthanised due to severe signs within 3 days. All vaccination regimes provided significant protection ($P < 0.0001$) against NDV challenge at 100 weeks of age ranging from 80% to 93% protection from clinical signs and mortality.

In conclusion, the claimed DOI of 80 weeks post vaccination is considered sufficiently supported by data. Challenge at 88 weeks post vaccination showed significant protection, and serology indicates a stable response up to this date. Efficacy of the vaccine against Newcastle disease is considered demonstrated with or without priming with ND vaccines.

Maternally derived antibodies (MDA)

No studies were performed. This is accepted, since at the age of vaccination MDAs are no longer relevant.

Interactions

The applicant has not provided data investigating interactions of the vaccine with any other veterinary medicinal product and therefore proposes to include a statement in Section 3.8 of the SPC that 'No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis'. This is considered acceptable.

Clinical trials

Four clinical trials were performed in the Netherlands. In these trials the safety and efficacy of Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS was evaluated under clinical conditions. The general set-up of the studies is described in the safety part. In these four clinical studies blood samples were collected and serological data were generated in a number of serological studies. In order to substantiate the efficacy claims, challenge experiments were performed in the laboratory with animals vaccinated in the field. The set-up of these studies and the results are discussed below for IBV and NDV only.

IBV

In study 1, serology was performed on samples taken during trial 1. Commercial layers in the two groups were vaccinated with various vaccines as per the farm vaccination scheme.

Blood samples were collected from at least 20 birds per flock at 12, 16, 18 and 22 weeks of age and then every 10 weeks until the end of the production period (approximately 86 weeks of age). Approximately 100 hens from the test flock were kept until 102 weeks of age and additional bleeds were taken from 20 birds at 92 and 102 weeks of age. IBV M41 and IBV 4/91 titres were determined, and antibody profiles for test and control layer flocks were similar for both IBV antigens.

In study 2, serology was performed on samples taken during trial 2. Commercial layers in the two

groups were vaccinated with various vaccines as per the farm vaccination scheme.

Blood samples were collected from 20 birds per flock at 12, 16, 18 and 22 weeks of age and then every 10 weeks until 92 weeks and at 100 weeks of age. IBV M41 and IBV 4/91 titres were determined, and antibody profiles for test and control layer flocks were similar for both IBV antigens.

In study 3, serology was performed on samples taken during the third field trial. Breeders in the two groups were vaccinated with various vaccines as per the farm vaccination scheme.

At 14, 19, 21, 25, 35, 45, 56, and 60 weeks of age blood samples were taken from 20 randomly selected hens in each group. Before the study birds went to slaughter in week 60, approximately 100 birds from each flock were transferred to a research centre and were kept until they were approximately 84 weeks of age. Blood sampling from 20 selected tagged hens per flock was carried out at approximately 5-week intervals. Antibody profiles for test and control breeder flocks were similar for both IBV antigens.

In study 4, serology was performed on samples taken during field trial 4. Breeders in the two groups were vaccinated with various vaccines as per the farm vaccination scheme.

IBV M41 and IBV 4/91 titres were determined, and antibody profiles for test and control breeder flocks were similar for both IBV antigens.

In conclusion, the antibody responses to IBV M41 and IBV 4/91 antigens were very similar after vaccination with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS compared to licensed inactivated Nobilis vaccines containing an IBV component when applied in commercial vaccination schemes in layers or breeders. It is noted that the birds of test and control flocks were primed with various combinations of live IBV vaccines, in accordance with the proposed use of Nobilis Multiriva IBm+ND as a booster vaccination. These results support the results of the pre-clinical studies.

NDV

The set-up of studies 1-4 is described above for IBV. NDV La Sota and Ulster HI titres were also determined in these studies. Test and control birds were vaccinated with Innovax-ND-IBD and Nobilis ND C2 prior to the test vaccine or control vaccine. Antibody profiles for test and control layer flocks were similar for both NDV antigens.

In study 5, two groups of 15 test or control vaccinated layers from field trial 2 and 15 non-vaccinated SPF birds were included. Challenge was performed with NDV Herts 33/56 at 30 weeks of age. All SPF birds were affected with NDV and euthanised within 4 days. None of the vaccinated birds showed any symptoms of NDV. Vaccination with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS vaccine within the commercial vaccination scheme used, including prior vaccination with Innovax ND IBD and Nobilis ND C2, provided full protection against NDV challenge at 18 weeks post vaccination.

Study 6 was performed using fifteen 65-week-old commercial broiler breeders taken from field study 4. The hens had been vaccinated with Nobilis ND C2 at 2 weeks of age, Nobilis ND Clone 30 at 8 weeks of age and Nobilis Multiriva RT+IBm+ND+EDS+Gm+REOm at 15 weeks of age. An additional group of fifteen 100-week-old SPF birds was used as unvaccinated controls. Challenge was performed at 65 weeks of age with NDV Herts 33/56, and birds were monitored for clinical signs for 21 days thereafter. All SPF birds were affected by NDV and euthanised within 4 days. None of the vaccinated birds showed any NDV-related symptoms during the observation period. Vaccination with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS vaccine within the commercial vaccination scheme used, including prior vaccination with Nobilis ND C2 and Nobilis ND Clone 30, provided full protection in breeders against NDV challenge at 50 weeks post vaccination.

Study 7 was set up as follows: fifteen 76-week-old commercial layers were taken from field study 3. The hens had been vaccinated with Innovax-ND-IBD at one day of age, Avinew NEO at 3 weeks of age, Nobilis ND Clone 30 at 7 weeks of age and Nobilis Multiriva RT+IBm+ND+EDS+Gm+REOm at 12 weeks of age. An additional group of fifteen 60-week-old SPF birds was used as unvaccinated controls. Challenge was performed at 76 weeks of age with NDV Herts 33/56, and birds were monitored for clinical signs for 21 days thereafter. Twelve out of thirteen control birds were affected by the challenge and euthanised within 4 days (92%). One bird in this group was alive and healthy at day 3 post challenge and had to be euthanised on welfare ground and was scored as 'protected'. In the vaccinated group, one bird showed ND-related signs on day 13 post challenge and was euthanised, resulting in 93% protection. Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS vaccine applied within the commercial vaccination scheme used, including prior vaccination with live NDV vaccines, provided full protection in layers against NDV challenge at 50 weeks post vaccination.

In conclusion, the onset, duration and magnitude of the anti-NDV antibody response in the field trials cannot be attributed to vaccination with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS alone. A booster effect was observed in the antibody titres from 4 weeks post vaccination with the test vaccine. Titres achieved were relatively stable up to 102 weeks of age and similar in flocks vaccinated with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS or existing inactivated viral vaccines from the Nobilis range. Challenge studies show that birds vaccinated according to a commercial vaccination schedule, including various priming vaccinations for NDV and booster with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS, were significantly protected from velogenic NDV challenge at least until 64 weeks post vaccination.

Overall conclusion on efficacy

IBV

The proposed indication for IBV is reduction of respiratory signs and egg drop caused by infectious bronchitis virus, strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype) and cross-protection against strains QX – D388 (GI-19 genotype), Var2 (GI-23 genotype) and Q1 (GI-16 genotype). The vaccine is to be used as a booster vaccination following priming with live vaccines against infectious bronchitis virus (e.g. Nobilis IB 4-91, Nobilis IB Ma5). The claimed onset of immunity is 4 weeks post vaccination and the duration of immunity 80 weeks post vaccination. A serological response was observed from 4 weeks post vaccination and can be reliably concluded to last for 75 weeks post vaccination.

For the use of Nobilis Multiriva IBm+ND as a booster, after priming with live IBV Ma5 and IBV 4/91 vaccines (at day of age), the efficacy against IBV M41 and IBV 4/91 challenge is supported by data at 45 and 81 weeks post vaccination. In addition, efficacy of the prime-boost regimen against IBV QX and IBV Var2 challenge at 25 weeks post vaccination was shown, while efficacy against IBV Q1 was shown at 11 weeks post vaccination.

The applicant has provided an overview of all the clinical data recorded in the IB vaccination-challenge studies. From these data it can be concluded that vaccination with a prime-boost scheme resulted in a reduction of coughing and respiratory clinical signs. Thus, protection against respiratory signs caused by IBV M41, IBV 4/91, IBV QX and IBV Var2 is considered adequately supported by data. Based on the totality of data, efficacy against respiratory clinical signs due to IBV Q1 can be expected and is accepted.

Serological analysis of the clinical trials shows that the antibody responses to both IBV M41 and IBV 4/91 were very similar in vaccinated groups compared to control-vaccinated groups. The results support the results of pre-clinical studies. It is noted that in all four clinical studies, birds of both test

and control flocks were primed with various combinations of live IBV vaccines at more than one timepoint prior to vaccination with the inactivated vaccine.

NDV

The proposed indication for NDV is reduction of mortality and clinical signs caused by NDV. The claimed onset of immunity is 4 weeks post vaccination and the duration of immunity 80 weeks post-vaccination. One serological study and four vaccination-challenge studies were performed in order to support OOI and DOI against NDV. Serology showed a response to vaccination from 4 weeks with measurable titres lasting at least until 88 weeks post vaccination. Priming with live ND vaccines resulted in consistently higher antibody titres. A challenge study performed in accordance with Ph. Eur. 0870 requirements showed that the vaccine blended at 100%, 75% or 50% complies with the test. Further challenge studies support the claimed OOI of 4 weeks and good levels of protection at 48 and 88 weeks post vaccination. This protection was achieved both with and without priming of birds with live ND vaccines.

In the four clinical trials, the birds were primed with various combinations of ND vaccines at more than one timepoint prior to vaccination with the test or control vaccine. Therefore, the onset, duration and magnitude of the anti-NDV antibody response cannot be attributed to vaccination with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS alone. A booster effect was observed in the antibody titres from 4 weeks post vaccination with test or control vaccines. Titres achieved were relatively stable up to 102 weeks of age and similar in test and control groups. Challenge studies in birds derived from the clinical trials showed that birds vaccinated according to a commercial schedule were significantly protected from velogenic NDV challenge at 30, 65 and 76 weeks of age (i.e. up to 64 weeks post booster vaccination with Nobilis Multiriva RT+IBm+ND+Gm+REOm+EDS).

Part 5 – Benefit-risk assessment

Introduction

Nobilis Multiriva IBm+ND is an emulsion for injection for chickens containing inactivated avian infectious bronchitis virus strain M41, inactivated avian infectious bronchitis virus strain 4/91, inactivated Newcastle disease virus strain Ulster and light liquid paraffin as adjuvant.

The vaccine is presented in packs containing 1 bottle of 300 ml (1000 doses) or 600 ml (2000 doses).

This vaccine is intended for use as a booster vaccination following priming with either live or inactivated vaccines in the vaccination schedule. The vaccine is to be administered intramuscularly as a single dose of 0.3 ml in the breast or thigh region from 8 weeks of age onwards, but no later than 3 weeks before the onset of lay.

The proposed withdrawal period is zero days.

The vaccine is intended to stimulate active immunity against infectious bronchitis virus and Newcastle disease virus as a booster vaccination and should be given to the chickens at least 4 weeks after administration of the primary vaccination.

At the time of submission, the applicant applied for the following indications:

For the active immunisation of chickens for:

- reduction of respiratory signs and egg drop caused by infectious bronchitis virus strains Massachusetts (GI-1 genotype), 4/91-793B (GI-13 genotype)
- reduction of mortality and clinical signs caused by Newcastle disease virus

Cross protection has been established for IBV strains QX-D388 (GI-19 genotype), Var2 (GI-23 genotype) and Q1 (GI-16 genotype).

The dossier has been submitted in line with the requirements for submissions under Article 8 of Regulation (EU) 2019/6 – full application.

Benefit assessment

Direct benefit

The proposed benefit of Nobilis Multiriva IBm+ND is its efficacy against IBV and NDV, which was investigated in a large number of well-designed pre-clinical and clinical studies conducted to an acceptable standard. The studies were performed with the full-combination vaccine, results are considered applicable for fall-out vaccines like Nobilis Multiriva IBm+ND.

The following indication is considered supported by the data provided:

For the active immunisation of chickens for:

- reduction of respiratory signs and egg drop caused by infectious bronchitis virus strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype).
- reduction of mortality and clinical signs caused by Newcastle disease virus.

Onset of immunity:

- 4 weeks post-vaccination.

Duration of immunity:

- 80 weeks post-vaccination

Cross protection has been established for IBV strains QX-D388 (GI-19 genotype), Var2 (GI-23 genotype) and Q1 (GI-16 genotype).

Additional benefits

Nobilis Multiriva IBm+ND is a combination of inactivated viral components, reducing the need for the application (injection) of different vaccines within a short timeframe. Compared to existing inactivated viral vaccine combinations, the dose volume is smaller which is an advantage with respect to injection-site safety and animal welfare.

Risk assessment

Quality

Information on development, manufacture and control of the finished product has been presented in a satisfactory manner. Quality data for each of the antigens is included in the respective vaccine antigen master files. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. The whole production process was evaluated at production scale and shown to be consistent. The data provided support the proposed 24-month shelf life.

Safety

Measures to manage the risks identified below are included in the risk management section.

Risks for the target animal

Administration of Nobilis Multiriva IBm+ND in accordance with SPC recommendations is generally well tolerated.

The safety of the vaccine in chickens at 7 weeks of age was confirmed in a GLP safety study and four clinical trials. The main reported adverse reaction is injection site swelling that was observed in some animals after being administered the standard dose. However, the effects were mild and transient.

Risk for the user

The CVMP concluded that user safety for this product is acceptable when used according to the SPC recommendations. Standard safety advice for veterinary medicinal products containing mineral oil is included in the SPC.

Risk for the environment

Nobilis Multiriva IBm+ND is not expected to pose a risk for the environment when used according to the SPC recommendations. Standard advice on waste disposal is included in the SPC.

Risk for the consumer:

The product is not considered to pose a risk to consumer safety. Based on the components, residue

studies are not required. The withdrawal period is set at zero days.

Special risks

None identified.

Risk management or mitigation measures

Appropriate information has been included in the SPC to inform on the potential risks of this product relevant to the target animal, user and environment and to provide advice on how to prevent or reduce these risks.

User safety

User safety risks have been identified. These risks have been addressed by the safety warnings included in the SPC.

Environmental safety

No specific environmental safety risks have been identified. Standard advice on waste disposal is included in the SPC.

Conditions or restrictions as regards the supply or safe and effective use of the VMP concerned, including the classification (prescription status)

The veterinary medicinal product is subject to a veterinary prescription.

Official control authority batch release may be required for this product according to national requirements.

Evaluation of the benefit-risk balance

At the time of submission, the applicant applied for the following indication:

“For the active immunisation of chickens for:

- reduction of respiratory signs and egg drop caused by infectious bronchitis virus (IBV) strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype).
- reduction of mortality and clinical signs caused by Newcastle disease virus (NDV).

Onset of immunity:

4 weeks post-vaccination.

Duration of immunity:

80 weeks post-vaccination

Cross protection has been established for IBV strains QX-D388 (GI-19 genotype), Var2 (GI-23 genotype) and Q1 (GI-16 genotype).”

The product has been shown to be efficacious for these indications and the CVMP accepted the indications as proposed by the applicant.

Based on the data presented to date, the overall benefit-risk balance is considered positive.

The product information has been reviewed and is considered to be satisfactory and in line with the assessment.

Conclusion

Based on the original and complementary data presented on quality, safety and efficacy, the Committee for Veterinary Medicinal Products (CVMP) concluded that the application for Nobilis Multiriva IBm+ND is approvable since these data satisfy the requirements for an authorisation set out in the legislation (Regulation (EU) 2019/6).

The CVMP considers that the benefit-risk balance is positive and, therefore, recommends the granting of the marketing authorisation for the above mentioned veterinary medicinal product.